Paper498151
Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).
Belt RJ and 5 others. Cancer Treat Rep, 1979. Cited by 140 papers, by iCite.
Cite this record
ConductScience Library. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Papers, record 498151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/498151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cisplatin | Major topic |
| Neoplasms | Major topic |
| Ascitic Fluid | |
| Half-Life | |
| Humans | |
| Kidney | |
| Mannitol | |
| Protein Binding |
Source PubMed
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 140 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38979778 | Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy. | Oncologist | 2024 | https://conductscience.org/library/papers/38979778 | PubMed |
| 37448551 | Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis. | Onco Targets Ther | 2023 | https://conductscience.org/library/papers/37448551 | PubMed |
| 33572935 | The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/33572935 | PubMed |
| 32508921 | Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease. | J Oncol | 2020 | https://conductscience.org/library/papers/32508921 | PubMed |
| 28856465 | Guidelines for treatment of renal injury during cancer chemotherapy 2016. | Clin Exp Nephrol | 2018 | https://conductscience.org/library/papers/28856465 | PubMed |
| 27586890 | Advanced hepatocellular carcinoma with hepatic vein tumor thrombosis and renal dysfunction after hepatic arterial infusion chemotherapy effectively treated by liver resection with active veno-venous bypass: report of a case. | BMC Cancer | 2016 | https://conductscience.org/library/papers/27586890 | PubMed |
| 19916578 | Cisplatin overdose: toxicities and management. | Drug Saf | 2009 | https://conductscience.org/library/papers/19916578 | PubMed |
| 12556954 | Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. | Br J Cancer | 2003 | https://conductscience.org/library/papers/12556954 | PubMed |
| 11219485 | Anticancer drug-induced kidney disorders. | Drug Saf | 2001 | https://conductscience.org/library/papers/11219485 | PubMed |
| 10864227 | Clinical pharmacokinetics and administration of established platinum drugs. | Drugs | 2000 | https://conductscience.org/library/papers/10864227 | PubMed |
| 8573296 | Comparative adverse effect profiles of platinum drugs. | Drug Saf | 1995 | https://conductscience.org/library/papers/8573296 | PubMed |
| 7987972 | Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/7987972 | PubMed |
| 7497604 | Long-term pharmacokinetic behavior of platinum after cisplatin administration. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7497604 | PubMed |
| 7200547 | [Pharmacokinetic of platin in plasma and urine of man under 1-, 8-, and 24 h-infusion with cis-dichlorodiamine-platin (II) (cis-DDP) (author's transl)]. | Klin Wochenschr | 1982 | https://conductscience.org/library/papers/7200547 | PubMed |
| 6883623 | Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer. | Cancer Chemother Pharmacol | 1983 | https://conductscience.org/library/papers/6883623 | PubMed |
| 6761344 | Phase II clinical trial of cis dichlorodiammine platinum (Cis DDP) in metastatic brain tumors. | J Cancer Res Clin Oncol | 1982 | https://conductscience.org/library/papers/6761344 | PubMed |
| 6189661 | Clinical pharmacokinetics of commonly used anticancer drugs. | Clin Pharmacokinet | 1983 | https://conductscience.org/library/papers/6189661 | PubMed |
| 4039488 | Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line. | Urol Res | 1985 | https://conductscience.org/library/papers/4039488 | PubMed |
| 4038382 | Clinical pharmacology of high-dose cisplatin. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/4038382 | PubMed |
| 3555940 | Pharmacokinetics of anticancer drugs in children. | Clin Pharmacokinet | 1987 | https://conductscience.org/library/papers/3555940 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/498151
GET https://conductscience.org/api/papers/v1/498151/cited_by?page=2